Similar articles

• CYP2D6 HhaI genotype and the neuroleptic malignant syndrome.

  Iwahashi K, Yoshihara E, Nakamura K, Ameno K, Watanabe M, Tsuneoka Y, Ichikawa Y, Igarashi K. Iwahashi K, et al. Neuropsychobiology. 1999;39(1):33-7. doi: 10.1159/000026557. Neuropsychobiology. 1999. PMID: 9892857 Clinical Trial.
• CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.

  Kato D, Kawanishi C, Kishida I, Furuno T, Matsumura T, Hasegawa H, Suzuki K, Hirayasu Y. Kato D, et al. Psychiatry Clin Neurosci. 2005 Aug;59(4):504-7. doi: 10.1111/j.1440-1819.2005.01405.x. Psychiatry Clin Neurosci. 2005. PMID: 16048458
• Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity.

  Kawanishi C, Furuno T, Onishi H, Sugiyama N, Suzuki K, Matsumura T, Ishigami T, Kosaka K. Kawanishi C, et al. Psychiatr Genet. 2000 Sep;10(3):145-7. doi: 10.1097/00041444-200010030-00007. Psychiatr Genet. 2000. PMID: 11204351
• Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.

  Kawanishi C, Hanihara T, Maruyama Y, Matsumura T, Onishi H, Inoue K, Sugiyama N, Suzuki K, Yamada Y, Kosaka K. Kawanishi C, et al. Psychiatr Genet. 1997 Autumn;7(3):127-9. doi: 10.1097/00041444-199723000-00007. Psychiatr Genet. 1997. PMID: 9323326
• [Drug-induced neuroleptic malignant syndrome].

  Kawanishi C, Furuno T, Kishida I. Kawanishi C, et al. Nihon Rinsho. 2007 Oct 28;65 Suppl 8:331-5. Nihon Rinsho. 2007. PMID: 18074558 Review. Japanese. No abstract available.